<DOC>
	<DOCNO>NCT00789867</DOCNO>
	<brief_summary>The study objectives assess safety , tolerability gene expression single dose non-viral CFTR gene therapy ( pGM169/GL67A ) administer nose lung patient cystic fibrosis .</brief_summary>
	<brief_title>Single Dose pGM169/GL67A CF Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Cystic fibrosis confirm sweat test genetic analysis Males females age 16 year Forced expiratory volume 1st second ( FEV1 ) &gt; 60 % predict value Clinical stability entry Prepared take effective contraceptive precaution duration participation study 3 month thereafter If take regular rhDNase ( pulmozyme ) willing , consider able independent medical carers , withhold treatment 24 hour 24 hour gene therapy dose Written inform consent obtain Permission inform GP participation study Infection Burkholderia cepacia complex organism MRSA Significant nasal pathology include polyp , clinicallysignificant rhinosinusitis , recurrent severe epistaxis ( nose bleeds ) Acute upper respiratory tract infection within last 2 week Previous spontaneous pneumothorax without pleurodesis Recurrent severe haemoptysis Current smoker Significant comorbidity include : 1 . Moderate/severe CF liver disease 2 . Significant renal impairment 3 . Significant coagulopathy Receiving 2nd line immunosuppressant drug methotrexate , cyclosporine , intravenous immunoglobulin preparation Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Single dose</keyword>
	<keyword>Pilot</keyword>
	<keyword>Safety</keyword>
	<keyword>Gene expression</keyword>
	<keyword>Tolerability</keyword>
	<keyword>CFTR gene</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Non-viral</keyword>
</DOC>